- Home
- RNR vs NBIX Comparison
RNR vs NBIX Comparison
Compare RNR & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNR
- NBIX
- Stock Information
- Founded
- RNR 1993
- NBIX 1992
- Country
- RNR Bermuda
- NBIX United States
- Employees
- RNR N/A
- NBIX N/A
- Industry
- RNR Property-Casualty Insurers
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RNR Finance
- NBIX Health Care
- Exchange
- RNR Nasdaq
- NBIX Nasdaq
- Market Cap
- RNR 13.5B
- NBIX 11.8B
- IPO Year
- RNR 1995
- NBIX 1996
- Fundamental
- Price
- RNR $264.35
- NBIX $123.29
- Analyst Decision
- RNR Buy
- NBIX Buy
- Analyst Count
- RNR 12
- NBIX 24
- Target Price
- RNR $289.50
- NBIX $163.91
- AVG Volume (30 Days)
- RNR 474.3K
- NBIX 1.1M
- Earning Date
- RNR 11-06-2024
- NBIX 10-30-2024
- Dividend Yield
- RNR 0.59%
- NBIX N/A
- EPS Growth
- RNR 127.60
- NBIX 97.40
- EPS
- RNR 69.12
- NBIX 3.73
- Revenue
- RNR $12,657,306,000.00
- NBIX $2,242,800,000.00
- Revenue This Year
- RNR N/A
- NBIX $26.97
- Revenue Next Year
- RNR $2.83
- NBIX $16.69
- P/E Ratio
- RNR $3.84
- NBIX $33.06
- Revenue Growth
- RNR 58.85
- NBIX 25.72
- 52 Week Low
- RNR $188.24
- NBIX $109.77
- 52 Week High
- RNR $300.00
- NBIX $157.98
- Technical
- Relative Strength Index (RSI)
- RNR 47.90
- NBIX 54.55
- Support Level
- RNR $254.72
- NBIX $115.27
- Resistance Level
- RNR $300.00
- NBIX $129.67
- Average True Range (ATR)
- RNR 8.13
- NBIX 3.28
- MACD
- RNR -0.51
- NBIX -0.33
- Stochastic Oscillator
- RNR 21.27
- NBIX 55.69
About RNR RenaissanceRe Holdings Ltd.
RenaissanceRe Holdings Ltd provides reinsurance and insurance solutions and related services. The company's core products include property, casualty and specialty reinsurance. Revenue is derived from three sources: net premiums earned from the insurance and insurance products sold; net investment income from the investment of capital funds and cash; and other income from the company's joint ventures, advisory services, and other items. The reportable segments of the company are the Property segment which includes catastrophe and other property reinsurance, and the Casualty and Specialty segment which is comprised of casualty and specialty reinsurance. It derives a majority of its revenue from the Casualty and specialty segment.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.